Schnitzler's syndrome improvement after anti-TNF-alpha therapy.
Aikawa
Nádia Emi
NE
Silva
Clovis Artur A
CA
Bonfá
Eloísa
E
Carvalho
Jozélio Freire de
JF
D000068879:Adalimumab; D000328:Adult; D000890:Anti-Infective Agents / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D003622:Dapsone / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage; D008297:Male; D011241:Prednisone / Q000008:administration & dosage; D020551:Pulse Therapy, Drug; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage; D019873:Schnitzler Syndrome / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000890:Anti-Infective Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D003622:Dapsone; D000068879:Adalimumab; D000068800:Etanercept; D011241:Prednisone